SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Brookdale Senior Living Inc. (BKD) (CIK 0001332349) (BKD) — Aug 13, 2020

Brookdale Senior Living Inc. (BKD) (CIK 0001332349)
Date: Aug. 13, 2020 · CIK: 0001332349 · Accession: 0000000000-20-007431

AI Filing Summary & Sentiment

File numbers found in text: 333-244394

Date
August 13, 2020
Author
Not clearly detected
Form
UPLOAD
Company
Brookdale Senior Living Inc. (BKD) (CIK 0001332349)

Letter

United States securities and exchange commission logo August 13, 2020 Chad C. White Executive Vice President, General Counsel and Secretary Brookdale Senior Living Inc. 111 Westwood Place, Suite 400 Brentwood, Tennessee 37027 Re:Brookdale Senior Living Inc. Registration Statement on Form S-3 Filed August 11, 2020 File No. 333-244394 Dear Mr. White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Laura Crotty at (202) 551-7614 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joseph A. Coco

Show Raw Text
United States securities and exchange commission logo
August 13, 2020
Chad C. White
Executive Vice President, General Counsel and Secretary
Brookdale Senior Living Inc.
111 Westwood Place, Suite 400
Brentwood, Tennessee 37027
Re:Brookdale Senior Living Inc.
Registration Statement on Form S-3
Filed August 11, 2020
File No. 333-244394
Dear Mr. White:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Laura Crotty at (202) 551-7614 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Joseph A. Coco